The Online Investor
OLI Premium
Contrarian Outlook
Stock Option Ideas
Preferred Stock Newsletter
ChartZero.com
ChartZero

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Mon., Jun. 24, 1:25 PM

Slide #12. Kura Oncology, Inc. Secondary Offering

Company: Kura Oncology, Inc. (NASDAQ:KURA)
Date announced: 6/18/2019
Shares Offered: 5,900,000
Date of Pricing: 6/19/2019
Price Per Share: $17.00
Secondary Offering Details: Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell shares of its common stock. In connection with the offering, Kura expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. -updated 6/19- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced the pricing of an underwritten public offering of 5,900,000 shares of its common stock at a price to the public of $17.00 per share. Kura has granted the underwriters a 30-day option to purchase up to an additional 885,000 shares of its common stock. The offering is expected to close on or about June 21, 2019, subject to customary closing conditions. The gross proceeds to Kura from the offering, excluding any exercise by the underwriters of their 30-day option to purchase additional shares, are expected to be $100.3 million, before deducting underwriting discounts and commissions and other offering expenses payable by Kura

Kura Oncology is a clinical-stage biopharmaceutical company engaged in developing medicines for the treatment of cancer. Co.'s key product candidate, tipifarnib, is a potent, selective and orally bioavailable inhibitor of farnesyl transferase. Co.'s second product candidate is KO-947, a potent and selective small molecule inhibitor of extracellular signal related kinase, which Co. is advancing as a potential treatment for patients with tumors that have mutations in, or other dysregulation of, the mitogen-activated protein kinase signaling pathway. Co.'s third program is focused on KO-539, a selective small molecule inhibitor of the menin-mixed lineage leukemia protein-protein interaction.

KURA SEC Filing Email Alerts Service

Open the KURA Page at The Online Investor »

Company Name:  Kura Oncology Inc
Website:  www.kuraoncology.com
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding KURA:  21
Total Market Value Held by ETFs:  $62.73M
Total Market Capitalization:  $723.00M
% of Market Cap. Held by ETFs:  8.68%
 

Open the KURA Page at The Online Investor (in a new window) »

June 24, 2019    1:25 PM Eastern
Quotes delayed 20 minutes



Strong Buy (4.00 out of 4)
89th percentile
(ranked higher than approx. 89% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings | www.TheOnlineInvestor.com | Copyright © 1998 - 2019, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.